Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec;416(30):7347-7355.
doi: 10.1007/s00216-024-05549-6. Epub 2024 Oct 7.

Plasmonics-enhanced spikey nanorattle-based biosensor for direct SERS detection of mRNA cancer biomarkers

Affiliations

Plasmonics-enhanced spikey nanorattle-based biosensor for direct SERS detection of mRNA cancer biomarkers

Joy Q Li et al. Anal Bioanal Chem. 2024 Dec.

Abstract

We present a plasmonics-enhanced spikey nanorattle-based biosensor for direct surface-enhanced Raman scattering (SERS) detection of mRNA cancer biomarkers. Early detection of cancers such as head and neck squamous cell carcinoma (HNSCC) is critical for improving patient outcomes in regions with limited access to traditional diagnostic methods. Our method targets Keratin 14 (KRT14), a promising diagnostic mRNA biomarker for HNSCC, using a sandwich hybridization approach with magnetic beads and SERS spikey nanorattles (SpNR). We synthesized SpNR with a core-gap-shell structure to enhance SERS signals, achieving a limit of detection of 90 femtomolar. A pilot study using clinical samples demonstrated the efficacy of our biosensor in distinguishing between tissue with positive or negative diagnosis for HNSCC, highlighting its potential for rapid and sensitive cancer diagnostics in low-resource settings. This plasmonic assay offers a promising avenue for portable and high-specificity detection of nucleic acid biomarkers, with implications for early cancer detection and improved patient care, especially in middle and low-resource settings.

Keywords: Biomarker; Biosensor; Nanoparticles; Plasmonics; SERS; mRNA.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethical disclosure and source of biological material: Informed consent was obtained from patients. All procedures for clinical tissue collection were reviewed and approved by the Institutional Review Board. Conflict of interest: The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
SpNR synthesis workflow (A). Schematic of SpNR DNA plasmonic assay (B). Inset of assay mechanism where SpNR are functionalized with reporter probes and magnetic beads are functionalized with capture probes which hybridize to an mRNA target (C). DNA probe sequences and their melting temperature and delta G when hybridized with the target sequence (D).
Fig. 2
Fig. 2
Scanning transmission electron microscopy – X ray diffraction (STEM-XRD) images of the Au@Ag Cages. The scale bar is 100 nm. SEM image (top left), Au only (top right), Ag only (bottom left), and Au/Ag overlay (bottom right).
Fig. 3
Fig. 3
Schematic representation of NR and SpNR synthesis and example transmission electron microscopy (TEM) of both (A). UV-vis absorbance spectra of goldcages, NR, and SpNR (B). SERS comparison of NR and SpNR at 1357 cm−1 peak (C).
Fig. 4
Fig. 4
Calibration curves using synthetic DNA target for KRT14 after 2-hour incubation (A). Background subtracted spectra with target range blank to 100pM KRT14 (B). Kinetic study of Projected SERS intensity at 1357cm−1 (C) and projected SERS spectra (D) for a range of incubation times 30 minutes to 2 hours. The inset shows and example of raw and background subtracted spectra. SERS spectra in (B, C) were offset for clarity.
Fig. 5
Fig. 5
Projected SERS peak intensity from SpNR plasmonic assay for 4 clinical samples (A). Corresponding RT-PCR values for each clinical sample (B). Combined projected SERS peak intensities from all clinical samples, grouped by sample status N=5, 6 with non-paired t-test P value =0.0011 (C). Projected SERS spectra from each clinical sample (D). SERS spectra in (D) were offset for clarity.

References

    1. Schenker Y, Arnold RM, Bauman JE, Heron DE, Johnson JT (2016) An enhanced role for palliative care in the multidisciplinary approach to high-risk head and neck cancer. Cancer 122 (3):340–343. doi:10.1002/cncr.29754 - DOI - PubMed
    1. Vigneswaran N, Williams MD (2014) Epidemiologic trends in head and neck cancer and aids in diagnosis. Oral Maxillofac Surg Clin North Am 26 (2):123–141. doi:10.1016/j.coms.2014.01.001 - DOI - PMC - PubMed
    1. Gallagher KE, LaMontagne DS, Watson-Jones D (2018) Status of HPV vaccine introduction and barriers to country uptake. Vaccine 36 (32 Pt A):4761–4767. doi:10.1016/j.vaccine.2018.02.003 - DOI - PubMed
    1. Pezzuto F, Buonaguro L, Caponigro F, Ionna F, Starita N, Annunziata C, Buonaguro FM, Tornesello ML (2015) Update on Head and Neck Cancer: Current Knowledge on Epidemiology, Risk Factors, Molecular Features and Novel Therapies. Oncology 89 (3):125–136. doi:10.1159/000381717 - DOI - PubMed
    1. Frohwitter G, Buerger H, van Diest PJ, Korsching E, Kleinheinz J, Fillies T (2016) Cytokeratin and protein expression patterns in squamous cell carcinoma of the oral cavity provide evidence for two distinct pathogenetic pathways. Oncol Lett 12 (1):107–113. doi:10.3892/ol.2016.4588 - DOI - PMC - PubMed

MeSH terms